BOSTON (June 27, 2012) — EvaluatePharma, the premier source for pharmaceutical and biotechnology sector analysis and consensus forecasts, has named Debbie Paul to the position of CEO Americas, EvaluatePharma USA Inc., effective immediately. In her new role, she leads EvaluatePharma's growing North American operations and its strategic expansion into Canada and Latin America.
Debbie Paul has been a key member of the EvaluatePharma executive team since 2004, most recently serving as Senior Vice President, North America. She brings knowledge gained through more than 25 years of truly diverse healthcare and life science industry experience, ranging from being a critical-care nurse manager to directing market research for a global pharmaceutical company.
Jonathan de Pass remains as chief executive of the U.K.-based parent company, EvaluatePharma Ltd.
Dr. de Pass founded EvaluatePharma in 1996, leading the way in creating new industry standards for consensus forecasting global drug sales and other performance metrics for the pharmaceutical and biotech sectors, as exemplified in two recent industry reports: "World Preview 2018: Embracing the Patent Cliff" and "Surveying Tomorrow's Biopharma Landscape: The NASDAQ Biotech Index Up Close." Dr. de Pass has since expanded EvaluatePharma into the United States and Japan markets, serving a growing demand for the company's data analysis.
"Debbie has clearly demonstrated her strategic leadership in growing and serving EvaluatePharma's expanding client base in the Americas," said Dr. de Pass. "Her experience and comprehensive understanding of the pharmaceutical and biotechnology marketplace, as well as the healthcare industry at large, gives her a talent for delivering actionable knowledge to all of the sector's participants, big and small. She stands out as the leader with the expertise to continue our growth during such a pivotal time for pharmaceutical and biotechnology industries in the Americas."
Prior to joining EvaluatePharma, Debbie Paul served as Director of Market Research at Sandoz, the generics division of global pharmaceuticals company Novartis AG, where her focus was strategic and product planning. She also worked in the pharmaceutical and medical products practice of management consultancy McKinsey & Co., Inc. Paul received her Masters of Business Administration from Rice University in Houston, Texas, following a 17-year career as a critical care nurse. She also holds a Bachelor of Science in Nursing from State University of New York in Albany.
Since 1996, EvaluatePharma has been the premier source for pharmaceutical and biotechnology sector analysis, delivering exclusive, trusted commercial insight into industry performance through its proprietary platform. EvaluatePharma is staffed by a team of 75 dedicated healthcare analysts employing rigorous methodologies to collate, organize and deliver the most-up-to-date commercial performance data available. An award winning editorial team of journalists writing under the EP Vantage name support EvaluatePharma's analysis. The EvaluatePharma services enable the life science community to make sound business decisions about value and opportunity. For the complimentary industry reports mentioned above and more information please visit www.evaluatepharma.com.